Patents by Inventor Gul Balwani
Gul Balwani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10064817Abstract: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g.Type: GrantFiled: October 28, 2011Date of Patent: September 4, 2018Assignee: Meda Pharmaceuticals Inc.Inventors: Phuong Grace Dang, Brian D. Lawrence, Gul Balwani, Alexander D. D'Addio
-
Patent number: 9919050Abstract: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions, into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g.Type: GrantFiled: August 23, 2013Date of Patent: March 20, 2018Assignee: Meda Pharmaceuticals Inc.Inventors: Phuong Grace Dang, Brian D. Lawrence, Gul Balwani, Alexander D. D'Addio
-
Patent number: 8895061Abstract: The present invention provides compositions comprising carisoprodol or pharmaceutically acceptable salts, esters or derivatives thereof. In certain embodiments, the invention provides pharmaceutical compositions comprising the skeletal muscle relaxant carisoprodol and one or more additional active agents, such as one or more nonsteroidal antiinflammatory drugs (NSAIDs). The invention further provides methods of use of such compositions in preventing, alleviating and/or treating musculoskeletal pain, muscle spasms, or other non-malignant painful conditions including methods in which the circulating levels of the active pharmaceutical form of carisoprodol are controlled by use of extended- or controlled-release formulations or by strict control of dosage regimen, so as to reduce the level of somnolence observed with other muscle relaxant compositions.Type: GrantFiled: March 3, 2008Date of Patent: November 25, 2014Assignee: Meda Pharmaceuticals Inc.Inventors: Gul Balwani, Harry J. Sacks, Bryan A. Roecklein, Benjamin Johns
-
Patent number: 8758816Abstract: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent.Type: GrantFiled: September 29, 2009Date of Patent: June 24, 2014Assignee: Meda Pharmaceuticals Inc.Inventors: Dennis Fuge, John Higson, Bryan A. Roecklein, Gul Balwani, Alexander D. D'Addio
-
Publication number: 20140158117Abstract: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions, into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g.Type: ApplicationFiled: August 23, 2013Publication date: June 12, 2014Applicant: Meda Pharmaceuticals Inc.Inventors: Phuong Grace DANG, Brian D. LAWRENCE, Gul BALWANI, Alexander D. D'ADDIO
-
Patent number: 8518919Abstract: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g.Type: GrantFiled: November 10, 2011Date of Patent: August 27, 2013Assignee: MEDA Pharmaceuticals Inc.Inventors: Phuong Grace Dang, Brian D. Lawrence, Gul Balwani, Alexander D. D'Addio
-
Publication number: 20120149690Abstract: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g.Type: ApplicationFiled: November 10, 2011Publication date: June 14, 2012Applicant: Meda Pharmaceuticals Inc.Inventors: Phuong Grace Dang, Brian D. Lawrence, Gul Balwani, Alexander D. D'Addio
-
Publication number: 20120083479Abstract: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g.Type: ApplicationFiled: October 28, 2011Publication date: April 5, 2012Applicant: Meda Pharmaceuticals Inc.Inventors: Phuong Grace Dang, Brian D. Lawrence, Gul Balwani, Alexander D. D'Addio
-
Patent number: 8071073Abstract: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g.Type: GrantFiled: November 22, 2005Date of Patent: December 6, 2011Assignee: MEDA Pharmaceuticals Inc.Inventors: Phuong Grace Dang, Brian D. Lawrence, Gul Balwani, Alexander D. D'Addio
-
Publication number: 20100189782Abstract: The present invention provides compositions comprising carisoprodol or pharmaceutically acceptable salts, esters or derivatives thereof. In certain embodiments, the invention provides pharmaceutical compositions comprising the skeletal muscle relaxant carisoprodol and one or more additional active agents, such as one or more nonsteroidal antiinflammatory drugs (NSAIDs). The invention further provides methods of use of such compositions in preventing, alleviating and/or treating musculoskeletal pain, muscle spasms, or other non-malignant painful conditions including methods in which the circulating levels of the active pharmaceutical form of carisoprodol are controlled by use of extended- or controlled-release formulations or by strict control of dosage regimen, so as to reduce the level of somnolence observed with other muscle relaxant compositions.Type: ApplicationFiled: March 3, 2008Publication date: July 29, 2010Inventors: Gul Balwani, Harry J. Sacks, Bryan A. Roecklein, Benjamin Johns
-
Publication number: 20100152147Abstract: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent.Type: ApplicationFiled: September 29, 2009Publication date: June 17, 2010Inventors: Dennis Fuge, John Higson, Bryan A. Roecklein, Gul Balwani, Alexander D. D'Addio
-
Publication number: 20070219253Abstract: Compositions consisting essentially of phenylephrine tannate, pyrilamine tannate, and guaifenesin which are effective when administered orally for the symptomatic relief of cough and nasal congestion associated with respiratory tract conditions such as the common cold, bronchial asthma, acute and chronic bronchitis are disclosed.Type: ApplicationFiled: September 17, 2003Publication date: September 20, 2007Inventors: Gul Balwani, Alexander D'Addio, Jeff Gazzara, Phuong Dang
-
Publication number: 20070020330Abstract: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g.Type: ApplicationFiled: July 14, 2006Publication date: January 25, 2007Applicant: MedPointe Healthcare Inc.Inventors: Phuong Dang, Brian Lawrence, Gul Balwani, Alexander D'Addio
-
Publication number: 20060110331Abstract: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g.Type: ApplicationFiled: November 22, 2005Publication date: May 25, 2006Applicant: MedPointe Healthcare Inc.Inventors: Phuong Dang, Brian Lawrence, Gul Balwani, Alexander D'Addio
-
Publication number: 20050232899Abstract: Stable aqueous formulations which are free of products derived from human or animal origin and which maintain high biological activity and high chemical and physical stability of alpha-type interferon, and proteins in general, for an extended period of time. Methods of producing stable aerosol formulations of the same for delivery to the lungs are also provided, as well as systems and methods of delivering the formulations to the lungs for systemic absorption.Type: ApplicationFiled: August 25, 2004Publication date: October 20, 2005Inventors: Gul Balwani, Brooks Boyd, John Whatley
-
Publication number: 20050019389Abstract: Pharmaceutical compositions containing a proanthocyanidin polymer composition which are useful for the treatment and prevention of secretory diarrhea are provided. The invention specifically relates to pharmaceutical formulations of a proanthocyanidin polymer composition which has been isolated from a Croton spp. or a Calophyllum spp. In particular, the invention relates to a formulation of a proanthocyanidin polymer composition which protects the composition from the effects of stomach acid after oral administration, particularly to those formulations which are enteric coated. The invention also relates to methods of producing a directly compressible proanthocyanidin polymer composition, as well as compositions containing the directly compressible proanthocyanidin polymer composition.Type: ApplicationFiled: August 17, 2004Publication date: January 27, 2005Inventors: Edward Rozhon, Atul Khandwala, Akram Sabouni, Gul Balwani, Jody Chan, David Sesin
-
Patent number: 6830744Abstract: Stable aqueous formulations which are free of products derived from human or animal origin and which maintain high biological activity and high chemical and physical stability of alpha-type interferon for an extended period of time. Methods of producing stable aerosol formulations of the same for delivery to the lungs are also provided, as well as systems and methods of delivering the formulations to the lungs for systemic absorption.Type: GrantFiled: May 31, 2002Date of Patent: December 14, 2004Assignee: Aradigm CorporationInventors: Gul Balwani, Brooks Boyd, John Whatley
-
Publication number: 20030223936Abstract: Stable aqueous formulations which are free of products derived from human or animal origin and which maintain high biological activity and high chemical and physical stability of alpha-type interferon for an extended period of time. Methods of producing stable aerosol formulations of the same for delivery to the lungs are also provided, as well as systems and methods of delivering the formulations to the lungs for systemic absorption.Type: ApplicationFiled: May 31, 2002Publication date: December 4, 2003Inventors: Gul Balwani, Brooks Boyd, John Whatley